Interference of medical contrast media on laboratory testing by Giuseppe Lippi et al.
©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Biochemia Medica 2014;24(1):80–8  http://dx.doi.org/10.11613/BM.2014.010 
80
Abstract
The use of contrast media such as organic iodine molecules and gadolinium contrast agents is commonplace in diagnostic imaging. Although there 
is widespread perception that side effects and drug interactions may be the leading problems caused by these compounds, various degrees of inter-
ference with some laboratory tests have been clearly demonstrated. Overall, the described interference for iodinate contrast media include inappro-
priate gel barrier formation in blood tubes, the appearance of abnormal peaks in capillary zone electrophoresis of serum proteins, and a positive bias 
in assessment of cardiac troponin I with one immunoassay. The interference for gadolinium contrast agents include negative bias in calcium asses-
sment with ortho-cresolphthalein colorimetric assays and occasional positive bias using some Arsenazo reagents, negative bias in measurement of 
angiotensin converting enzyme (ACE) and zinc (colorimetric assay), as well as positive bias in creatinine (Jaffe reaction), total iron binding capacity 
(TIBC, ferrozine method), magnesium (calmagite reagent) and selenium (mass spectrometry) measurement. Interference has also been reported in 
assessment of serum indices, pulse oximetry and methaemoglobin in samples of patients receiving Patent Blue V. Under several circumstances the 
interference was absent from manufacturer-supplied information and limited to certain type of reagents and/or analytes, so that local verification 
may be advisable to establish whether or not the test in use may be biased. Since the elimination half-life of these compounds is typically lower than 
2 h, blood collection after this period may be a safer alternative in patients who have received contrast media for diagnostic purposes.
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Introduction
Total quality in laboratory diagnostics is a multifac-
eted and challenging enterprise, which entails 
standardization and monitoring of a number of 
activities throughout the total testing process (1). 
Although several lines of evidence now attest that 
most laboratory errors emerge from manually in-
tensive steps of the preanalytical phase (2,3), a va-
riety of analytical errors may still occur in the ana-
lytical phase, which basically entail random errors 
during measurements, inappropriate calibration of 
methods, volume displacement, matrix effects, in-
strument carryover as well as analytical inter fe re-
nce(s) (4). In a recent survey, published by Plebani 
and Carraro in 2007, problems in the analytical 
phase were responsible for nearly 15% of all diag-
nostic mistakes (5). Analytical inaccuracy not rec-
ognized (e.g., release of results despite unaccepta-
ble internal quality control data due to problems 
in calibration-verification procedure) and instru-
ment-caused random errors (e.g., pipetting prob-
lems, presence of interfering substances or short 
sampling) were found to be the most frequent 
mistakes in this phase of total testing process. It is 
also noteworthy that the vast majority of these er-
rors (i.e. approx 90%) was considered as preventa-
ble, thus reinforcing the notion that analytical er-
rors are nothing but unlikely and additional efforts 
should be placed for preventing their occurrence. 
The aim of this review is to provide an overview 
about the interference of medical contrast media 
on laboratory testing.
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Analytical interference
Some definitions have been provided for the con-
cept of “analytical interference”, which basically 
describe the same phenomenon under different 
perspectives. These include “the cause of clinically 
significant bias in the measured analyte concentra-
tion due to the effect of another component or prop-
erty of the sample” (6), “the systematic error of meas-
urement caused by a sample component, which does 
not, by itself, produce a signal in the measuring sys-
tem” (7), “the effect of a substance present in an ana-
lytical system, which causes deviation of the meas-
ured value from the true value” (8), and again “a sub-
stance or process that falsely alter an assay result” (9). 
Regardless of different terms used for defining an 
identical concept, a reliable synthesis has been 
provided by the Clinical and Laboratory Standards 
Institute (CLSI), wherein a bias in measurement 
may be due to lack of specificity of detection sys-
tem, suppression of an indicator reaction, inhibi-
tion (or activation) of the measured analyte, along 
with other cause of specimen-dependent bias (6). 
The interfering substance is not necessarily a 
source of the measuring system signal, but may 
cause either increase or decrease of its indicated 
value.
The interfering substances are hence basically clas-
sified in (i) endogenous, when are present or origi-
nate from biological elements normally found in 
patient samples, thus including metabolic prod-
ucts, cell-free haemoglobin (10,11), hyperbiliru-
binemia (11), hyperlipidaemia (11,12), proteins (es-
pecially paraproteins) (13), autoantibodies or het-
erophilic antibodies (14), excessive analyte concen-
tration and cross-reacting substances; or (ii) exog-
enous, when these compounds are not normally 
found in the specimens, and hence include differ-
ent types of drugs and intravenous therapeutics, 
chemicals, natural products, component of collec-
tion system (i.e. parts of vial, gel separator or tube 
stopper) (15), additives such as anticoagulants (e.g., 
EDTA, heparin, buffered sodium citrate) or proco-
agulants (e.g., thrombin or other enzyme added to 
accelerate sample clotting), preservatives added 
for maintaining sample quality (e.g., sodium azide, 
penicillin G, streptomycin and amphotericin B, be-
statin, leupeptin and aprotinin) (16), contaminants 
inadvertently introduced during sample handling 
(17), and products of carryover contamination (18). 
The interference on analytical measurements may 
be complex and even multifaceted, thus involving 
different mechanisms, including (i) immunochemi-
cal interference, when the compound or its me-
tabolites cross-react with the measured analyte; 
(ii) reaction interference, when the compound or 
its metabolites catalyze or inhibit some step of the 
chemical or immunochemical reaction; (iii) photo-
metric interference, when the compound or its 
metabolites have absorption (or emission) peaks 
that overlap with those of the measured chro-
mogen (9); as well as (iv) dilutional effects due to 
variable amounts of infusion fluid that may accom-
pany the administration of diagnostic agents. Re-
gardless of the underlining causes, this article is 
specifically addressed to provide an overview on 
the interference of medical diagnostic media on 
results of laboratory testing.
Medical contrast media
Medical contrast media (or contrast agents) in-
clude a category of compounds that are conven-
tionally used to enhance the contrast of structures 
or fluids within the body during medical imaging. 
Several types of agents have been developed for 
use in medical imaging, which can be roughly be 
classified according to the imaging modalities 
where they are used. Organic iodine molecules 
(e.g., iohexol, iodixanol and ioversol) and barium 
sulphate are the most common types of contrast 
media for enhancing x-ray-based imaging meth-
ods (19), whereas gadolinium contrast agents (ion-
ic, neutral, albumin-bound or polymeric) are typi-
cally used in magnetic resonance imaging (MRI) 
(20).
The chemical characteristics of these agents have 
substantially changed over time. The so called 
first-generation ionic contrast media are substan-
tially monomers composed by a single benzene 
ring that ionize in solution with an oxidation state 
of -1. They are hence characterized by up to 7-fold 
greater osmolality than plasma and a remarkable 
risk of causing contrast-induced nephropathy (21). 
In order to prevent this life-threatening condition, 
a new generation of non-ionic contrast media has 
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been developed. These basically include non-ionic 
monomers and non-ionic dimers, which dissolve 
in water but do not dissociate. Therefore, generat-
ing a fewer number of particles in solution, they 
are characterized by an osmolality that is very sim-
ilar to that of blood (i.e. up to 2-3 fold that of blood 
for low-osmolar media, and the same as blood for 
iso-osmolar media), but also by a greater viscosity 
(21).
Interference from organic iodine molecules
Although some evidences have been published 
about the potential analytical interference of con-
trast media in laboratory diagnostics, it is impor-
tant to mention here that the problems caused by 
these compounds may also impact on sample 
quality and integrity. Interestingly, Spiritus et al. 
(22) first observed that the presence of these high-
density molecules may increase the density of 
plasma or serum to such an extent to exceed that 
of gel separators, thus interfering with correct for-
mation of barrier between sample matrix and cells 
in the blood tube, so causing the gel to partially or 
completely float at the top of serum (or plasma). 
Identical observations were more recently report-
ed by Kaleta et al. (23), who identified two cases of 
migration of gel separator above serum in patients 
receiving iodinated contrast media during coro-
nary angiography and percutaneous intervention, 
and by Daves et al. (24), who reported the case of 
unusual positioning of gel separator, which mi-
grated at the topmost layer in the serum sample of 
a patient who received a tri-iodinated non-ionic 
water-soluble contrast dye during a revasculariza-
tion procedure for acute myocardial infarction.
As more specifically regards analytical interfer-
ence, Lin et al. (25) reported a significant (positive) 
bias in results of troponin I (TnI) measured with 
one assay in the presence of iodinated contrast 
media. In a first in vivo part of this study involving 
45 subjects undergoing coronary angiography 
with iopromide, the concentration of TnI measured 
with Opus Magnum cTnI immunoassay system (Be-
hring Diagnostics) was lower than the diagnostic 
threshold (0.5 ng/mL) in all samples drawn before 
the procedure, but increased over this threshold in 
38 samples (rate 0.84) collected 5 min after the 
procedure, and in 4 samples (rate 0.09) collected 
30 min afterwards. The concentration of TnI re-
turned to values lower than the diagnostic cut-off 
of the assay 1 h after the end of the procedure. In a 
second experiment, the concentration of TnI was 
compared using Opus Magnum and ACCESS Ac-
cuTnI (Beckman Coulter) in samples taken from 25 
patients undergoing coronary angiography with 
iopromide. The values obtained with Opus Mag-
num cTnI increased again over the diagnostic 
threshold of the assay in 21 patients (rate 0.81) af-
ter 5 and 30 min after the procedure, whereas 
those of Access AccuTnI always remained lower 
than the cut-off of the method (i.e. 0.15 ng/mL). 
When as many as 12 different iodinated contrast 
media were spiked to serum samples, a positive 
bias was always recorded using Opus Magnum 
cTnI, whereas a significant increase of troponin val-
ues was only seen with one contrast medium (i.e. 
poppy-seed oil) using Access AccuTnI. Interesting-
ly, the magnitude of bias in TnI measurements on 
Opus Magnum cTnI was directly correlated with 
the concentration of contrast media.
Bossuyt et al. (26) first described a potential inter-
ference in capillary zone electrophoresis in serum 
samples of patients receiving intravascular radio-
opaque agents. In all electropherograms of these 
patients, an abnormal peak (“spike”) was observed 
in the alpha-2-globulin fraction, 2-4 h after injec-
tion of contrast media. The peak was at the anodal 
side of alpha-2-globulin fraction in the presence of 
amidotrizoate, at centre of alpha-2 fraction in the 
presence of ioxitalamate, and at cathodal side of 
alpha-2 fraction with iohexol. In all circumstances 
the peak could not be found on standard agarose 
electrophoresis. The interference was then attrib-
uted to absorbance at 214 nm of both proteins and 
iodinated contrast media, since these compounds 
absorb the light in the far ultraviolet and peak be-
tween 237 and 244 nm. Arranz-Peña et al. (27) also 
investigated the effect of 12 opaque contrast me-
dia on serum capillary zone electrophoresis, by 
adding each compound to a control serum to 
achieve the expected concentration after bolus in-
jection for radiographic examination (i.e. 7.5 g/L). 
Interesting, each iodinated contrast media caused 
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the appearance of an abnormal peak in the alpha-
2-zone of the electropherogram. All peaks had the 
same form and location as the extra peak found in 
electropherograms of patients who are infused 
with contrast agents. These findings were con-
firmed in other following investigations (28-30).
Finally, Potter et al. (31) reported that certain con-
trast agents may interfere with paper chromatog-
raphy and paper electrophoresis of organic acids 
and ultraviolet-absorbing compounds such as pu-
rine bases and their derivatives, as well as in other 
methods involving ultraviolet absorption.
Interference from gadolinium contrast agents
Gadolinium contrast agents are powerful chela-
tors, so that their leading path of interference is at-
tributable to this specific property. In an earlier re-
port, Normann et al. (32) investigated the influence 
of the non-ionic MRI contrast medium gadodi-
amide on colorimetric assessment (i.e. photomet-
ric test using ortho-cresolphthalein; OCP) of serum 
calcium, and showed that results of measurement 
exhibited a significant negative bias as compared 
with quantification by ion-selective electrodes. 
The extent of interference was also strictly corre-
lated with the concentration of contrast medium. 
In a following publication, Lin et al. (33) investigat-
ed the potential interference of linear (gadodi-
amide and gadopentetate) or macrocyclic gado-
linium complexes (i.e. gadoterate) on serum calci-
um measured by conventional colorimetric tech-
niques (i.e. OCP or methylthymol blue reagents). 
Interestingly, no interference was found when mix-
ing gadopentetate or gadoterate with serum, 
whereas the solution containing gadodiamide 
produced a concentration-related bias in meas-
ured calcium concentration using both methods. 
With the aim of evaluating the frequency of spuri-
ous hypocalcemia after gadodiamide-enhanced 
MRI, Prince et al. (34) reviewed serum calcium val-
ues measured with OCP colorimetric assay in 896 
inpatients undergoing gadodiamide-enhanced 
magnetic resonance imaging (MRI). The mean re-
duction of serum calcium measurement after 
gadodiamide injection was 0.08 ± 0.91 mmol/L, 
with a maximum variation of 0.47 mmol/L. A de-
crease was observed in approx 58% of patients un-
dergoing gadodiamide-enhanced MRI, and in 
nearly 16% of cases this reduction was from a nor-
mal calcium value to hypocalcemic status. Calcium 
reduction was significantly associated with serum 
creatinine level (r = 0.39; P < 0.001), gadodiamide 
dose (r = 0.37, P < 0.001), and inversely correlated 
with time between gadodiamide injection and 
blood collection (r = -0.28, P < 0.001). Even more 
importantly, seven patients were inappropriately 
treated with intravenous calcium and eleven with 
oral calcium as a result of spurious critical hypocal-
cemia. The presence of significant interference 
was also confirmed with in vitro studies, wherein 
gadodiamide interfered with colorimetric assess-
ment of serum calcium. Additional cases of mod-
erate to severe pseudohypocalcemia were also re-
ported by Doorenbos et al. (35) (serum calcium 
measured with a not specified colorimetric tech-
nique) after gadodiamide-enhanced MRI angiog-
raphy, Decupere et al. (36) using an OCP assay after 
gadodiamide-enhanced vascular MRI of the verte-
brobasilar system, and Williams et al. (37) using an 
OCP method after gadodiamide-enhanced MRI. In 
another study, Kang et al. (38) carried out an ex-
perimental investigation to assess the extent of in-
terference due to three gadolinium contrast agents 
on serum calcium assessment with OCP and arse-
nazo dye. Two of these compounds (i.e. gadodi-
amide and gadoversetamide) produced a marked 
negative bias using OCP-based methods (from 
-0.10 to -0.47 mmol/L), and a significant positive 
bias using the arsenazo-based assays (from 0.07 to 
0.15 mmol/L). On the other hand, a third gadolin-
ium contrast agent (i.e. gadopentate) did not af-
fect calcium measurement with either method. 
The concentration of serum calcium was also as-
sessed in 116 samples of patients receiving gado-
diamide, and was found to be lower with one OCP 
method that with the other. The magnitude of bias 
was inversely associated with estimated glomeru-
lar filtration rate (GFR) and length of time since ad-
ministration of contrast medium. Proctor et al. (39) 
investigated the interference of gadodiamide, 
gadoversetamide, gadopentetate, dimeglumine, 
and gadoteridol on several calcium assays, and 
found that gadolinium contrast agents caused no 
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interference on two arsenazo assays, one induc-
tively coupled plasma mass spectrometry (ICP-MS) 
technique, one ion selective electrode assay and 
one ionized calcium method, whereas a negative 
bias was observed with three OCP methods (be-
tween -9 and -24% for gadodiamide and between 
-9 and -22% for gadoversetamide, respectively). 
Löwe et al. (40) also evaluated the interference of 
commercially available gadolinium-containing 
contrast-enhancing agents with calcium measured 
with either an arsenazo-based colorimetric meth-
od or an OCP assay. Although gadopentetate and 
gadobenate did not significantly altered the con-
centration of calcium measured with either meth-
od, the presence of gadodiamide and gadoverset-
amide caused a positive bias with arsenazo-based 
colorimetry and a negative one with the OCP as-
say. Brown et al. (41) administered intravenous in-
jections of four different gadolinium contrast 
agents (i.e. gadodiamide, gadopentetate dimeglu-
mine, and gadoteridol) to 12 healthy volunteers 
and measured serum calcium levels with an OCP 
and arsenazo III methods, as well as with ICP-MS, 
at fixed time points from 5 to 240 min after injec-
tion. It was hence found a significant and negative 
bias in serum calcium concentration measured 
with the OCP assay after injection of both gado-
versetamide and gadodiamide. For both com-
pounds the effect was evident as soon as 5 min af-
ter injection, and persisted for up to 100 min. An 
increase of serum calcium assayed with the arse-
nazo III method was also observed 5 min after in-
jection of gadodiamide.
Datta and Dasgupta (42) assessed whether a new 
arsenazo III dye for measuring calcium may be bi-
ased by the presence of gadodiamide or gadover-
setamide in serum. Although the concentration of 
calcium measured with a traditional OCP method 
was reduced by approx 40% in the presence of 
gadolinium contrast agents, no significant bias (i.e. 
< 4%) was observed in that measured with the 
new assay. More recently, Löwe et al. (43) assessed 
the extent of interference from gadobutrol and 
gadoxetate with colorimetric assessment of calci-
um (arsenazo and OCP methods). The results of 
calcium measurements were comparable for both 
contrast agents and only small fluctuations were 
observed, which mostly fell within the usual range 
of experimental error.
Even more interestingly, Gandhi et al. (44) assessed 
the clinical and economic impact of spuriously de-
creased serum calcium values (OCP method) due 
to interference from gadoversetamide in 766 pa-
tients in whom the compound had been adminis-
tered for diagnostic purposes. In approx 20% of 
patients who had calcium reassessed with an OCP 
assay less sensitive to gadoversetamide interfer-
ence, the difference between methods was great-
er than 0.175 mmol/L and in 2% of patients this dif-
ference was greater than 0.35 mmol/L. Calcium 
supplementation was started in 22 out of 56 pa-
tients (i.e. 39%) with marked spurious hypocal-
cemia. The total additional expenditure (including 
reagents and laboratory technologists time) for 
troubleshooting spurious hypocalcemia was esti-
mated at $76.5 / day.
As regards analytical interference on other labora-
tory parameters, Proctor et al. (39) studied the po-
tential interference of gadodiamide, gadoverseta-
mide, gadopentetate, dimeglumine, and gadoteri-
dol in as many as 41 serum assays. Significant in-
terference was found for angiotensin-converting 
enzyme (ACE; -74% for gadodiamide and -68% for 
gadoversetamide, respectively), total iron binding 
capacity measured with the ferrozine method 
(TIBC; 27 to 49% for gadodiamide and 21 to 29% 
for gadoversetamide, respectively), zinc measured 
with a manual colorimetric assay (-85% for gadodi-
amide, -74% for gadoversetamide, -58% for gado-
pentetate and -13% for gadoteridol, respectively). 
The concentration of magnesium was also found 
to be significantly increased using calmagite meth-
od (+17% for gadodiamide and +24% for gadover-
setamide, respectively), but not when measured 
with methylthymol blue, xylidyl blue and forma-
zan assays. Haylor et al. (45) assessed the effect of 
five gadolinium contrast agents (i.e., gadodiamide, 
gadoversetamide, gadopentetate, gadobutrol and 
gadoterate) on serum creatinine measured with 
both Jaffe kinetic reaction and an enzymatic assay. 
Although no substantial bias could be observed 
with the enzymatic assay for any contrast agent, 
the Jaffe kinetic reaction exhibited a significant 
positive bias in the presence of large doses (i.e. 
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≥ 2.5 mmol/kg body weight) of gadodiamide, 
gadodiamide and gadoversetamide, yielding to 
false positive results. An occasional report of posi-
tive bias in selenium measurement by inductively 
coupled plasma-quadrupole mass spectrometry 
after administration of a contrast agent containing 
gadolinium has also been reported by Walter et al. 
(46).
Irrespective of the precise mechanisms involved 
(either biding of dye to gadolinium, or binding of 
calcium to the free contrast media), several lines of 
evidence attest that calcium measurement may be 
highly unreliable in the presence of gadolinium 
contrast agents (Table 1). Particular caution should 
hence be used when interpreting results of calci-
um (and other parameters) in patients undergoing 
MRI with gadolinium contrast agents. Since the 
elimination half-life of the these compounds is ap-
proximately 90 to 100 min in patients with pre-
served renal function (41), laboratory testing 
should be delayed until complete elimination of 
contrast media because the effect of residual dye 
is heterogeneous, and test results may be biased 
due to dilutional effects or unpredictable interfer-
ence with specific laboratory assays. An additional 
issue is the potential interference of some of these 
compounds on appropriate formation of the gel 
barrier in primary blood tubes. Although serum or 
plasma may be extracted from beneath the gel 
barrier, collection of another sample should be 
seen as a more reliable approach to safeguard pa-
tient safety.
Interference from Patent Blue V
Patent Blue V is a synthetic inert dye that is typi-
cally used during cancer surgery for identifying 
lymph node metastases (47). Darby and Broom-
head (48) spiked normal serum samples with in-
creasing concentrations of this chemical substance 
(from 4.9 to 22.7 mg/L), and found a linear dose-
response positive interference in lipaemic index 
and a linear dose-response negative interference 
Study Contrast agent Method(s) Bias Reference
Normann et al., 1995 Gadodiamide OCP Negative (32)
Lin et al., 1999 Gadodiamide OCPMethylthymol blue
Negative
Negative (33)
Prince et al., 2003 Gadodiamide OCP Negative (34)
Doorenbos et al., 2003 Gadodiamide OCP Negative (35)

















Decupere et al., 2005 Gadodiamide OCP Negative (36)
Williams et al., 2005 Gadodiamide OCP Negative (37)






















Datta et al., 2009 Gadodiamide OCP Negative (42)
OCP - ortho-cresolphthalein colorimetric assay
Table 1. Interference on gadolinium contrast agents on calcium assessment.
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in hemolysis and icteric indices. No significant in-
terference was however observed in the measure-
ment of several clinical chemistry analytes, includ-
ing sodium, potassium, urea, creatinine, bilirubin, 
alanine aminotransferase, gamma-glutamyltrans-
ferase, aspartate aminotransferase, magnesium, 
creatine kinase, lactate dehydrogenase, amylase, 
albumin, calcium and phosphate. A similar effect 
on serum indices was further reported by McTag-
gart et al. (49). A variable interference of has also 
been reported in pulse oximeter readings and 
methaemoglobin measurement using different 
analyzers (50).
Conclusions
The use of contrast media is now commonplace in 
diagnostic imaging. Although there is a wide-
spread perception that side effects and potential 
drug interactions may be the leading problems 
caused by these compounds, various degrees of 
interference with some laboratory tests have been 
clearly demonstrated. Incidentally, a wrong test re-
sult may jeopardize patient safety to a similar ex-
tent than a mishandled therapeutic act (51), and so 
every possible effort should be put in place for 
preventing or identifying potential sources of er-
rors throughout the total testing process.
Overall, the described interference for iodinate 
contrast media include the appearance of abnor-
mal peaks in capillary zone electrophoresis of se-
rum proteins, positive bias in assessment of TnI 
with one immunoassay, whereas that for gadolin-
ium contrast agents include a negative bias in cal-
cium assessment with OCP assay and an occasion-
al positive bias using some arsenazo reagents, a 
negative bias in measurement of ACE and zinc 
(colorimetric assay) and a positive bias in creati-
nine (Jaffe kinetic reaction), TIBC (ferrozine meth-
od), magnesium (calmagite reagent) and selenium 
(inductively coupled plasma-quadrupole mass 
spectrometry) assessment. Occasional interfer-
ence has also been reported in serum indices, 
pulse oximetry and methaemoglobin in patients 
receiving Patent Blue V. Under several circum-
stances the interference was absent from manu-
facturer-supplied information and limited to cer-
tain type of reagents and/or analytes. As such, 
whenever a laboratory cannot rely on a manufac-
turer’s verification, local assessment of potential 
bias according to the current CLSI guidelines (6) 
may be advisable to establish whether or not the 
test in use may be biased by the presence of sig-
nificant amounts of contrast agents in serum or 
plasma. Since the elimination half-life of all these 
compounds is typically lower than 2 h (41), collec-
tion of blood specimens after this period may be a 
safer alternative in patients who have recently re-
ceived contrast media for diagnostic purposes. Al-
ternatively, laboratory assays that are proven to be 
insensitive to this kind of interference should be 
preferred, at least when testing samples from pa-
tients who have recently received medical contrast 
agents.
One major unresolved issue, however, is to distin-
guish between in vivo and ex vivo effects of con-
trast agents. Lukasiewicz, for example, reported 
that the administration of non-ionic iodinated con-
trast media (i.e. iomeprol and iopromide) signifi-
cantly increased the plasma concentrations of pro-
thrombin fragment 1+2 (F1+2) and thrombin-anti-
thrombin complexes (TAT), but not those of D-
dimer and beta-thromboglobulin (β-TG) (52). Al-
though it was hence concluded that non-ionic 
agents may exert significant effects on hemostatic 
activation, the biological pathway leading to alter-
ation of F1+2, TAT and D-dimer is generally over-
lapping (53), so that it could not be definitely as-
certained whether these changes were the result 
of a real biological effect or rather of analytical ar-
tefacts, especially if one considers that the current 
guidelines of the European Society of Urogenital 
Radiology (ESUR) Contrast Media Safety Commit-
tee report that all contrast media have anticoagu-
lant and not pro-coagulant properties (54).
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